Abbott Laboratories has received FDA approval for TactiFlex Duo, a focal ablation catheter capable of delivering both pulsed-field and radiofrequency energy. The system enters a rapidly expanding pulsed-field ablation market with a different proposition: instead of replacing thermal ablation entirely, it lets electrophysiologists choose between energy types during the same procedure.
Abbott’s TactiFlex Duo combines pulsed field ablation and radiofrequency energy in one contact-force catheter, giving electrophysiologists a way to move between tissue-selective PFA and conventional thermal ablation without changing platforms during an AFib procedure.
Abbott Laboratories has secured FDA De Novo authorization for Libre Duo 10 Day, the first wearable in the United States to continuously monitor ketones and the first device globally to continuously measure glucose and ketones together.
Avricore Health’s HealthTab will distribute Abbott’s Afinion 2 through NHS-linked pharmacies, combining rapid HbA1c and lipid testing with a connected platform for community-based screening.
FDA approves Freenome’s SimpleScreen CRC blood test as Abbott plans a fall launch. See its benefits, limits and colonoscopy requirement.
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?